EP1408031A1 — Pyrolidine derivatives useful in treatment of hepatitis C virus infection
Assigned to 3 D Gene Pharma · Expires 2004-04-14 · 22y expired
What this patent protects
The present invention relates to novel hepatitis C virus ("HCV") protease inhibitors or other flavivirus protease inhibitors of formula, pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to…
USPTO Abstract
The present invention relates to novel hepatitis C virus ("HCV") protease inhibitors or other flavivirus protease inhibitors of formula, pharmaceutical compositions containing one or more such inhibitors, methods for preparing such inhibitors, uses of these compounds to treat hepatitis C and related disorders together with their use for their activity towards NS3 serine protease, intermediary compounds for the method of preparation of said compounds and screening methods. The invention specifically discloses novel chemical compounds as inhibitors of the HCV serine protease.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.